133 related articles for article (PubMed ID: 28031051)
1. The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.
Chang KL; Lee MY; Chao WR; Han CP
Hum Genomics; 2016 Dec; 10(1):40. PubMed ID: 28031051
[TBL] [Abstract][Full Text] [Related]
2. High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients.
Chao WR; Lee YJ; Lee MY; Sheu GT; Han CP
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):1072-1077. PubMed ID: 34794740
[TBL] [Abstract][Full Text] [Related]
3. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.
Lee YJ; Lee MY; Ruan A; Chen CK; Liu HP; Wang CJ; Chao WR; Han CP
Oncotarget; 2016 Dec; 7(50):82097-82103. PubMed ID: 27888800
[TBL] [Abstract][Full Text] [Related]
4. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
7. Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.
Lin WL; Kuo WH; Chen FL; Lee MY; Ruan A; Tyan YS; Hsu JD; Chiang H; Han CP
Ann Surg Oncol; 2011 Aug; 18(8):2388-94. PubMed ID: 21347793
[TBL] [Abstract][Full Text] [Related]
8. Both
Koo CL; Lee MY; Chao WR; Han CP
J Cancer Res Ther; 2022; 18(3):862-863. PubMed ID: 35900578
[No Abstract] [Full Text] [Related]
9. Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.
Chay WY; Kwok LL; Tiong WN; Krisna SS; Lim KH; Iyer NG; Goh LK; Tan DS
Int J Gynecol Cancer; 2018 Mar; 28(3):428-436. PubMed ID: 29465505
[TBL] [Abstract][Full Text] [Related]
10. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
11. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
12. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
13. [KRAS mutations analysis in mucinous epithelial lesions of the endometrium].
Zheng XZ; Zhan Y; Ma JH; Xu HW; Zhi WX; Chen TB; Qin XY; Wang P; Zhang LH; Gu YC; Jin YL; Zhu L; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):687-690. PubMed ID: 30220122
[No Abstract] [Full Text] [Related]
14. KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
Hershkovitz D; Vlodavsky E; Simon E; Ben-Izhak O
Pathol Int; 2013 Dec; 63(12):611-4. PubMed ID: 24422958
[TBL] [Abstract][Full Text] [Related]
15. HER2 amplification and overexpression are significantly correlated in mucinous epithelial ovarian cancer.
Chao WR; Lee MY; Lin WL; Chen CK; Lin JC; Koo CL; Sheu GT; Han CP
Hum Pathol; 2014 Apr; 45(4):810-6. PubMed ID: 24656091
[TBL] [Abstract][Full Text] [Related]
16. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
17. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
19. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
[TBL] [Abstract][Full Text] [Related]
20. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
